Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (GB:0I3Q)
LSE:0I3Q
Corcept Therapeutics (0I3Q) Share Price & Analysis
0 Followers
0I3Q Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.88 - $36.44
Previous Close$35.42
Volume341.00
Average Volume (3M)730.00
Market Cap
$3.71B
Enterprise Value$3.30B
Total Cash (Recent Filing)$410.76M
Total Debt (Recent Filing)$76.00K
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Jul 29, 2024EPS Estimate
$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding104,112,088
10 Day Avg. Volume126
30 Day Avg. Volume730
Standard Deviation0.16
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.17
Price to Sales (P/S)6.08
Price to Cash Flow (P/CF)132.80
P/FCF Ratio132.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.30
Enterprise Value/Gross Profit6.93
Enterprise Value/Ebitda23.92
Forecast
1Y Price Target
$45.88Price Target Upside29.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Corcept Therapeutics News
Bulls Say, Bears Say
Bulls Say
EarningsSales of Korlym remain strong, and the company appears on track to achieve its revenue guidance.
Product ApprovalRelacorilant achieved, with statistical significance, both major endpoints in the study.
Regulatory PathThe regulatory path for relacorilant in Cushing’s is clear, with a high probability of receiving FDA approval, given that the study met its primary endpoint.
Bears Say
Clinical TrialsThere remains clinical risk on the overall outcome of the GRACE trial, as well as the regulatory and commercial future associated with it.
Legal IssuesTEVA filed a lawsuit against CORT claiming Korlym's orphan pricing is egregious and that some of CORT's patents are invalid.
Sales PracticesTEVA's accusations of doctor kickbacks is essentially a re-hash of the ongoing NJ USAO's investigations into CORT's sales practices.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
2.00% Other Institutional Investors
98.00% Public Companies and
Individual Investors
0I3Q FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest share price was $20.88 and its highest was $36.44 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Currently, no data Available
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Jul 29, 2024 which is in 2 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on May 01, 2024. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.03.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is $0.23.
How many shares outstanding does Corcept Therapeutics Inc. have?
Currently, no data Available
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.25 in its last earnings report, beating expectations of $0.22. Following the earnings report the stock price went up 3.748%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Among the largest hedge funds holding Corcept Therapeutics Inc.’s share is Royce & Associates LLC. It holds Corcept Therapeutics Inc.’s shares valued at 8M.
---
Corcept Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.88 (29.54% Upside)
$45.88 (29.54% Upside)
Blogger Sentiment
Bullish
GB:0I3Q Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.88%
12-Months-Change
Fundamentals
Return on Equity
21.75%
Trailing 12-Months
Asset Growth
6.16%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
---
0I3Q Earnings Call
Q1 2024
0:00 / 0:00
---
0I3Q Stock 12 Month Forecast
Average Price Target
$45.88
▲(29.54% Upside)
Technical Analysis
Best Analysts Covering 0I3Q
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+21.56%
reiterated a buy rating last month
Copying Edward Nash's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +21.56% per trade.
---